These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24706516)

  • 21. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
    Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
    Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K; Mendell-Harary J; Tachibana M; Masumoto H; Oguma T; Kojima M; Kunitada S
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
    Yin OQ; Tetsuya K; Miller R
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
    Fuji T; Fujita S; Tachibana S; Kawai Y
    J Thromb Haemost; 2010 Nov; 8(11):2458-68. PubMed ID: 20723033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers
.
    Chen X; Liu D; Wu Y; Liu Y; Song H; Jiang J; Hu P
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):256-263. PubMed ID: 28025966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.
    Krekels EH; Niebecker R; Karlsson MO; Miller R; Shimizu T; Karlsson KE; Ruff CT; Simonsson US; Jönsson S
    Clin Pharmacokinet; 2016 Sep; 55(9):1079-90. PubMed ID: 26951208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.
    Parasrampuria DA; Truitt KE
    Clin Pharmacokinet; 2016 Jun; 55(6):641-55. PubMed ID: 26620048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
    Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
    Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment.
    Shimizu T; Tachibana M; Kimura T; Kumakura T; Yoshihara K
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):484-491. PubMed ID: 28032482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
    Shirasaki Y; Morishima Y; Shibano T
    Thromb Res; 2014 Apr; 133(4):622-8. PubMed ID: 23932349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
    Mendell J; Johnson L; Chen S
    J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
    Narita Y; Hamamura K; Kashiyama M; Utsumi S; Kakizoe Y; Kondo Y; Ishitsuka Y; Jono H; Irie T; Mukoyama M; Saito H; Kadowaki D; Hirata S; Kitamura K
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
    Wolzt M; Samama MM; Kapiotis S; Ogata K; Mendell J; Kunitada S
    Thromb Haemost; 2011 Jun; 105(6):1080-90. PubMed ID: 21544313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology and laboratory testing of the oral Xa inhibitors.
    Samama MM; Meddahi S; Samama CM
    Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.